logo

Axsome Therapeutics, Inc. (AXSM)



Trade AXSM now with
  Date
  Headline
2/6/2019 7:10:18 AM Axsome Therapeutics Receives FDA Agreement Under SPA For MOMENTUM Phase 3 Trial Of AXS-07 In Migraine
1/30/2019 7:11:26 AM Axsome Therapeutics Begins Phase 2 Trial Of AXS-12 In Narcolepsy; Expects Topline Results In Q2'19
1/7/2019 6:04:02 AM Axsome Therapeutics Unveils AXS-05 Achieves Primary Endpoint In Phase 2 Trial In Major Depressive Disorder
12/10/2018 7:07:31 AM Axsome : IDMC Recommends Continuation Of Trial Evaluating AXS-05 Versus Placebo In Alzheimer’s Disease Agitation
11/14/2018 7:10:37 AM Axsome Therapeutics Completes Patient Enrollment In ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder
11/9/2018 7:09:19 AM Axsome Therapeutics Q3 Net Loss $8.3 Mln Or $0.31/Shr Vs Net Loss Of $6.4 Mln Or $0.27/Shr Last Year
10/17/2018 7:03:23 AM Axsome Therapeutics Receives Orphan Drug Designation From FDA For AXS-12 For Treatment Of Narcolepsy
10/16/2018 7:09:26 AM Axsome Therapeutics Announces Next CNS Product Candidate, AXS-12 For Narcolepsy Treatment
10/11/2018 7:16:52 AM Axsome Therapeutics To Focus On Growing Core CNS Portfolio
9/28/2018 7:09:20 AM Axsome Therapeutics Unveils $8.9 Mln Registered Direct Offering